Visual And Refractive Outcomes Of Small Incision Lenticule Extraction With Visumax 800 In 1500 Eyes
Published 2025 - 43rd Congress of the ESCRS
Reference: FP26.03 | Type: Free paper | DOI: 10.82333/4znw-mh11
Authors: Luis Izquierdo* 1 , Cathiana Garcia 2 , Ignacia Zenteno 2 , Melisa Camargo 2 , Rolando Rojas 2 , Maria A Henriquez 3
1Research Department,Oftalmosalud Institute of Eyes,Lima,Peru;San Fernando School of Medicine,Universidad Nacional Mayor de San Marcos,Lima,Peru, 2Research Department,Oftalmosalud Institute of Eyes,Lima,Peru, 3Research Department,Oftalmosalud Institute of Eyes,Lima,Peru;Faculty of Human Medicine,Universidad Ricardo Palma ,Lima,Peru
Purpose
To assess visual and refractive outcomes of 1500 eyes that underwent SMILE with the VisuMax 800 femtosecond laser (Carl Zeiss Meditec AG).
Setting
NETHRADHAMA SUPERSPECIALITY EYE HOPSITAL, BANAGLORE, KARNATAKA, INDIA
Methods
This retrospective study includes 1500 eyes (770 patients) younger than 45 years with CDVA of 20/20 or better who were treated with SMILE using VisuMax 800. The surgery was performed by a single experienced surgeon using a standard technique and 3 month and 1 year follow up data was analysed
Results
1500 eyes with mean age of 27.25±4.746 years with 39.48% males and 60.52% females were included in the study. At 3 months, 98% of eyes had UDVA 20/20 or better with an efficacy index of 1.01. Mean pre-operative SE was -4.170±1.860D, and at 3 months it was -0.025±0.120D (p=0.000). 18.4% had gained 1 line of CDVA and 9.2% had loss of 1 line with safety index 1.61. Post-operative SE was within ±0.5D and ±1D in 99% and 100% eyes respectively. 98.4% and 100% eyes showed astigmatism £0.5D and £1D respectively. No eyes lost 2 or more lines of CDVA. At 3 months, OSI was 0.844±0.486, which was close to preoperative values, with a mean change of 0.11. Similar analysis was done for 386 eyes at 12 months which demonstrated good refractive stability
Conclusions
The VisuMax 800, with centration guidance (CentraLign®) and cyclotorsion adjustment features (OcuLign®), showed safe and effective outcomes for the treatment of myopia and myopic astigmatism in a large cohort of 1500 eyes